功能性内分泌肿瘤多起源于胃肠道系统内分泌细胞,较为罕见,以大量分泌原发性肽为其特征。此外也分泌多种继发性肽类物质,其效应尚未完全明瞭。二者复杂的相互作用可改变临床综合征。许多敏感的激发试验可引起功能性内分泌肿瘤的肽分泌,已证明有重要的诊断作用,并有可能发现手术后残留或复发的微小病灶。生长激素释放抑制因子(Somatostatin)和Sandostatin(SMS)一前者的一种类似物一可抑制许多功能性内分泌肿瘤原发肽的释放,但对于继发性肽释放的抑制尚无系统研究。作者对5例确诊为胰腺功能性内分泌肿瘤患者进行研究,以求确证:功能性内分泌肿瘤是否有继发性肽类分泌或分泌亢进;标准的激发试验可否刺激其原发性和继发性肽的分泌, Functional endocrine tumors mostly originate from the gastrointestinal system endocrine cells, are relatively rare, with a large number of secreted primary peptide is characterized. In addition also secrete a variety of secondary peptides, the effect is not yet fully understood. The complex interaction between the two can change the clinical syndrome. Many sensitive provocation tests can cause peptide secretion in functional endocrine tumors and have demonstrated important diagnostic utility and the potential for detection of small lesions that persist or recur after surgery. One of the analogues of Somatostatin and Sandostatin (SMS), a former one, inhibits the release of many functional endocrine tumor primary peptides, but there is no systematic study on the inhibition of secondary peptide release. The authors studied five patients diagnosed with pancreatic endocrine tumors in order to confirm: functional endocrine tumors have secondary secretion or secretion of hypersecretion; standard stimulation test can stimulate the primary and secondary peptides Secretion,